Kylo-04

N/A

Report date: 2025/06/23 16:58:45
NME

Base Information

Drug NameKylo-04
Drug Alias NameHT-101Kylo-04
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionHBsAg inhibitorsHepatitis B e Antigens inhibitorsHepatitis B virus replication inhibitors
TargetsHepatitis B Surface AntigensHepatitis B e Antigens
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHangzhou Hygieia Pharmaceuticals Co LtdSuzhou Xingyao Kunze Biopharmaceutical Co LtdXiamen Ganbaoli Biopharmaceutical Co Ltd +[4] 
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Xingyao Kunze Biopharmaceutical Co LtdXiamen Ganbaoli Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, ChronicHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A